​

23andMe (ME) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

ME Stock Forecast

23andMe (ME) stock forecast, based on 2 Wall Street analysts, predicts a 12-month average price target of $0.42, with a high of $0.42 and a low of $0.42. This represents a -87.76% decline from the last price of $3.43.

- $1 $2 $3 $4 $5 High: $0.42 Avg: $0.42 Low: $0.42 Last Closed Price: $3.43

ME Stock Rating

23andMe stock's rating consensus is Buy, based on 2 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 1 Buy (50.00%), 1 Hold (50.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 2 0 1 1 Strong Sell Sell Hold Buy Strong Buy

ME Forecast vs Benchmarks

TypeNameUpside
Stock23andMe-87.76%
SectorHealthcare Stocks 25.20%
IndustryDiagnostics & Research Stocks16.01%

Price Target Trends

1M3M12M
# Anlaysts--1
Avg Price Target--$0.42
Last Closing Price$3.43$3.43$3.43
Upside/Downside---87.76%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Nov, 24-11--2
Oct, 24-11--2
Sep, 24-11--2
Aug, 24-11--2
Jul, 24-11--2
Latest Price Target by Analysts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Sep 16, 2024Daniel GrosslightCitigroup$0.42$0.3423.53%-87.76%
Nov 29, 2022Berenberg Bank$7.00$2.76153.62%104.08%
Latest Upgrade/Downgrade by Analysts
DateCompanyPrevious RatingNew RatingRating Change
Sep 16, 2024CitigroupNeutralNeutralhold
May 28, 2024CitigroupNeutralNeutralhold
May 24, 2024Cowen & Co.BuyBuyhold
Apr 15, 2024CitigroupNeutralNeutralhold

Financial Forecast

EPS Forecast

$-25 $-20 $-15 $-10 $-5 $0 Mar 22 Mar 23 Mar 24 Mar 25 Mar 26 Mar 27
Mar 22Mar 23Mar 24Mar 25Mar 26Mar 27
Reported$-0.60$-0.69$-1.40---
Avg Forecast$-10.47$-13.57$-22.48$-12.59$-10.64$-7.80
High Forecast$-10.47$-13.57$-22.48$-12.59$-10.64$-7.80
Low Forecast$-10.47$-13.57$-22.48$-12.59$-10.64$-7.80
Surprise %-94.27%-94.92%-93.77%---

Revenue Forecast

$150M $180M $210M $240M $270M $300M Mar 22 Mar 23 Mar 24 Mar 25 Mar 26 Mar 27
Mar 22Mar 23Mar 24Mar 25Mar 26Mar 27
Reported$271.89M$299.49M$219.64M---
Avg Forecast$275.63M$298.41M$211.43M$166.68M$198.42M$251.39M
High Forecast$275.63M$298.41M$205.35M$166.68M$198.42M$251.39M
Low Forecast$275.63M$298.41M$217.50M$166.68M$198.42M$251.39M
Surprise %-1.36%0.36%3.88%---

Net Income Forecast

$-5B $-4B $-3B $-2B $-1B $0 Mar 22 Mar 23 Mar 24 Mar 25 Mar 26 Mar 27
Mar 22Mar 23Mar 24Mar 25Mar 26Mar 27
Reported$-217.49M$-311.66M$-666.70M---
Avg Forecast$-4.98B$-322.85M$-534.95M$-299.60M$-253.22M$-185.67M
High Forecast$-4.98B$-322.85M$-534.95M$-299.60M$-253.22M$-185.67M
Low Forecast$-4.98B$-322.85M$-534.95M$-299.60M$-253.22M$-185.67M
Surprise %-95.64%-3.47%24.63%---

ME Forecast FAQ

Is 23andMe stock a buy?

23andMe stock has a consensus rating of Buy, based on 2 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 1 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that 23andMe is a favorable investment for most analysts.

What is 23andMe's price target?

23andMe's price target, set by 2 Wall Street analysts, averages $0.42 over the next 12 months. The price target range spans from $0.42 at the low end to $0.42 at the high end, suggesting a potential -87.76% change from the previous close price of $3.43.

How does 23andMe stock forecast compare to the average forecast of its sector, industry, and investment themes?

23andMe stock forecast shows a -87.76% downside, underperforming the average forecast for the healthcare stocks sector (25.20%) and underperforming the diagnostics & research stocks industry (16.01%).

What is the breakdown of analyst ratings for 23andMe over the past three months?

  • November 2024: 0% Strong Buy, 50.00% Buy, 50.00% Hold, 0% Sell, 0% Strong Sell.
  • October 2024: 0% Strong Buy, 50.00% Buy, 50.00% Hold, 0% Sell, 0% Strong Sell.
  • September 2024: 0% Strong Buy, 50.00% Buy, 50.00% Hold, 0% Sell, 0% Strong Sell.

What is 23andMe’s EPS forecast?

23andMe's average annual EPS forecast for its fiscal year ending in March is -12.59 for 2025, a 799.29% increase from the reported $-1.4 in 2024. The prediction for 2026 is $-10.64, and $-7.8 for 2027.

What is 23andMe’s revenue forecast?

23andMe's average annual revenue forecast for its fiscal year ending in March is $166.68M for 2025, a -24.11% decrease from the reported $219.64M in 2024. The forecast for 2026 is $198.42M, and $251.39M for 2027.

What is 23andMe’s net income forecast?

For its fiscal year ending in March, 23andMe's average annual net income forecast is $-300M for 2025, reflecting a -55.06% decrease from the reported $-667M in 2024. The projection for 2026 is $-253M, and $-186M for 2027.